Status:
WITHDRAWN
RA Effect on Cell Surface Molecules in Vivo
Lead Sponsor:
Ottawa Hospital Research Institute
Conditions:
HIV Infections
Eligibility:
MALE
18-65 years
Phase:
PHASE1
Brief Summary
This study will follow a group of healthy male participants for about 18 weeks to see the effect of taking Acitretin on their immune cells
Detailed Description
Retinoids have been shown in in vitro and ex vivo models to have the ability to reverse latency reactivating the HIV reservoir and the potential for selective eradication of HIV-harbouring cells. We f...
Eligibility Criteria
Inclusion
- Male gender
- Age 18 - 65
- Able to provide informed consent
- Willingness to participate in study treatment and follow-up
- Willingness for serial phlebotomy and storage and future viro-immunological assays
Exclusion
- Female gender
- Participants with a known hypersensitivity/allergy to the acitretin.
- Participants who are actively participating in an experimental therapy study or who have received experimental therapy within the last 1 year.
- Participants who are a poor medical risk because of other systemic diseases or active uncontrolled infections including HIV, Hepatitis B or C, and tuberculosis
- Participants with impaired glucose tolerance including prediabetes or diabetes mellitus, dyslipidemia, or liver dysfunction
- Previous or current history of mood disorder, psychosis, or suicidality
- Participants currently receiving ongoing treatment with methotrexate, tetracyclines, or other retinoids
Key Trial Info
Start Date :
January 7 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 8 2019
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03753867
Start Date
January 7 2019
End Date
May 8 2019
Last Update
March 4 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.